Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
A

Ratings ESG MSCI

Ratings Eli Lilly and Company: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Highlights: Eli Lilly and Company
  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses: Eli Lilly and Company
  • With an expected P/E ratio at 46.09 and 33.1 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company is highly valued given the cash flows generated by its activity.
  • The company is not the most generous with respect to shareholders' compensation.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Rating Financials

Eli Lilly and Company SectorUnited States
Fundamentals
Growth
Revenue growth
EPS growth
FCF growth
Profitability
EBITDA Margin
EBIT Margin
Net Margin
Capital Efficiency
ROA
ROCE
ROE
Financial Health
Gearing
Leverage
Capital Intensity
Balance sheet growth
Long Term balance sheet growth
Long term revenue growth
Long term EPS growth
More ratings

Rating Valuation

Eli Lilly and Company SectorUnited States
Global Valuation
Enterprise value
EV/Revenue
EV/EBITDA
EV/FCF
Equity Valuation
P/E
PBR
Dividend Yield
EV/EBIT
CAPEX/Revenue
More ratings

Rating Consensus

Eli Lilly and Company SectorUnited States
Consensus
Analysts' buy/sell recommendations
Analysts' recommendations evolution (1 year)
Analysts' recommendations evolution (4 months)
Analysts' target price
Analysts' target price evolution (1 year)
Analysts' target price evolution (4 months)
Analysts' recommendations evolution (7 days)
Target Price evolution (7 days)
More ratings

Rating Business Predictability

Eli Lilly and Company SectorUnited States
Visibility
Analysts' coverage
Financial estimates divergence
Analysts' recommendations divergence
Analysts' Target price divergence
Surprise rates

Rating Revisions

Eli Lilly and Company SectorUnited States
Financial revisions
Revenue revisions (1 year)
Revenue revisions (4 months)
EPS revisions (1 year)
EPS revisions (4 months)
EPS revisions (7 days)
Revenue revisions (7 days)
More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
944B
A
504B
BBB
395B
AA
345B
AA
281B
A
260B
AAA
244B
A
217B
A
176B
A
145B
BBB
Average 351.05B
AA
Weighted average by Cap.
AA
See all sector ratings
  1. Stock Market
  2. Equities
  3. LLY Stock
  4. Ratings Eli Lilly and Company